Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
Conditions
Interventions
acalabrutinib
vistusertib
Locations
11
United States
Research Site
Fairway, Kansas, United States
Research Site
Bethesda, Maryland, United States
Research Site
Rochester, Minnesota, United States
Research Site
Omaha, Nebraska, United States
Research Site
Hackensack, New Jersey, United States
Research Site
Nashville, Tennessee, United States
Start Date
June 29, 2017
Primary Completion Date
November 20, 2019
Completion Date
November 20, 2019
Last Updated
January 6, 2021
NCT05139017
NCT06043011
NCT06528301
NCT05672173
NCT07255963
NCT05940272
Lead Sponsor
Acerta Pharma BV
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions